Mergers and Acquisitions Overview - 89bio, Inc. will be acquired by Roche for $14.50 per share in cash, plus a contingent value right of up to $6.00 per share, with investigations into the Board's fiduciary duties regarding fair process and value [2] - Barinthus Biotherapeutics plc will merge with Clywedog Therapeutics, with Barinthus shareholders receiving one share of the new company for each ADS or ordinary share owned, and Clywedog shareholders receiving 4.358932 shares, raising questions about the Board's fiduciary duties [4] - Dayforce, Inc. is set to be acquired by Thoma Bravo for $70.00 per share in cash, with an enterprise value of $12.3 billion, while investigations focus on whether the deal consideration is fair compared to the 52-week high of $82.69 [6] - Verint Systems Inc. will also be acquired by Thoma Bravo for $20.50 per share, with investigations into the Board's fiduciary duties and the deal's fairness compared to the 52-week high of $34.80 [8]

Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB) at a price of $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain milestone payments of up to an aggregate of $6.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of September 17, 2025, among Roche Holdi ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. 89bio, Inc. is one of them. 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardiometabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, pegozafermin, is a long-acting FGF21 analog designed to treat moderate to severe MASH, including advanced fibrosis, as well as related metabolic disorders. In ...

Core Viewpoint - Monteverde & Associates PC is investigating the proposed sale of 89bio, Inc. to Roche Holdings, Inc., focusing on whether the deal is fair for shareholders [1]. Company Overview - Monteverde & Associates PC is a national class action securities firm based in the Empire State Building, New York City, recognized for recovering millions for shareholders [2][3]. - The firm has a successful track record in trial and appellate courts, including the U.S. Supreme Court [2]. Transaction Details - Under the proposed transaction, 89bio shareholders will receive $14.50 per share in cash at closing, along with a non-tradeable contingent value right for potential additional payments of up to $6.00 per share based on specified milestones [1].

Group 1 - Roche announced the acquisition of 89bio, Inc for a deal that could reach $3.5 billion [2] - The acquisition reflects ongoing interest in potential buyouts within the biotech and biopharma sector [2] - The Biotech Forum offers a model portfolio of 12-20 high upside biotech stocks along with trade discussions and market commentary [2] Group 2 - The Biotech Forum provides weekly research and option trades to its members [2] - The forum includes live chat features for discussing specific covered call trades [1] - Analyst disclosures indicate beneficial long positions in various biotech stocks [3]

Group 1 - The proposed sale of 89bio, Inc. to Roche Holding AG involves shareholders receiving $14.50 per share in cash at closing [1] - In addition to the cash payment, shareholders will also receive a non-tradeable contingent value right for potential payments of up to an aggregate of $6.00 per share [1]

Core Viewpoint - 89bio Inc. is set to be acquired by Roche for $3.5 billion, leading to a significant surge in its stock price, reaching a record high [1][3]. Group 1: Acquisition Details - Roche has entered into a definitive agreement to acquire 89bio Inc. to enhance its portfolio in innovative therapies for cardiovascular, renal, and metabolic diseases [3]. - The acquisition involves a tender offer for all outstanding shares of 89bio at a price of $14.50 per share, along with potential milestone payments of up to $6.00 per share, bringing the total deal value to approximately $3.5 billion [4]. - The acquisition price represents a 52% premium over 89bio's 60-day volume weighted average price as of September 17 [5]. Group 2: Stock Performance - During intra-day trading, 89bio's shares soared by as much as 86% to a 52-week high of $15.06, ultimately closing up 85.15% at $14.96 [2].

Summary of Key Points Core Viewpoint - Top Wall Street analysts have revised their ratings on several companies, indicating a shift in market sentiment towards these stocks [1]. Company-Specific Updates - **United Parcel Service, Inc. (UPS)**: - BMO Capital analyst Fadi Chamoun downgraded UPS from Outperform to Market Perform and reduced the price target from $125 to $96. The shares closed at $85.05 [6]. - **89bio, Inc. (ETNB)**: - HC Wainwright & Co. analyst Andrew S. Fein downgraded the rating from Buy to Neutral with a price target of $14.5. The shares closed at $14.96. Additionally, Wolfe Research analyst Andy Chen also downgraded ETNB from Outperform to Peer Perform [6]. - **Replimune Group, Inc. (REPL)**: - JP Morgan analyst Anupam Rama downgraded REPL from Neutral to Underweight. The shares closed at $3.46 [6].

Market Overview - U.S. stock index futures are showing mixed performance as investors react to a recent Federal Reserve interest rate cut and anticipate upcoming economic data [1][2] - Major indexes closed at record highs on Thursday, with the Dow Jones Industrial Average up 0.27%, S&P 500 rising 0.48%, and Nasdaq Composite increasing by 0.94% [3] Economic Indicators - The 10-year Treasury yield rose by 2 basis points to 4.13%, while the 2-year yield increased by 1 basis point to 3.58% [2] - Strong labor market data indicated a drop in U.S. Weekly Initial Jobless Claims to 231K for the week ending September 13, below expectations, which reassured investors about economic stability [3] Upcoming Economic Data - Key economic data releases include Flash Purchasing Managers' Index (PMI) surveys and the U.S. core Personal Consumption Expenditures (PCE) price index, scheduled for September 26, 2025 [5] - Other significant upcoming data includes revised GDP numbers, consumer confidence data, home sales figures, durable goods orders, and inventories [5] Corporate Earnings - Several companies are set to report earnings, including MoneyHero Limited, IperionX Limited ADR, and FedEx, which reported better-than-expected FQ1 earnings and projected 4%-6% revenue growth for fiscal year 2026 [6][11] - 22nd Century Group's shares surged 31% after announcing it is now debt-free, while 89bio's shares skyrocketed 85% following Roche's agreement to acquire the biotech firm for $14.50 per share [11] Key Corporate News - Nvidia shares advanced 3.5% after announcing a $5 billion investment in Intel, which saw its stock surge over 23% [7] - CoreWeave's shares rose 0.3% after Loop Capital initiated coverage with a "Buy" rating, highlighting its growing prominence among chip giants and AI labs [11] - FedEx's strong results positively impacted UPS, which saw its stock increase by 2% [11] Stock Movements - Red Cat Holdings' shares fell 12% after pricing an offering of 15.6 million shares at $9.60 each [11] - Nucor's shares slipped 4% after guiding its Q3 EPS to $2.05-$2.15, below the consensus estimate of $2.56 [11]

Market Performance - The S&P 500 Index closed up +0.48%, the Dow Jones Industrials Index up +0.27%, and the Nasdaq 100 Index up +0.95% on Thursday, with all three indexes reaching new record highs [1][2] - September E-mini S&P futures rose +0.50%, and September E-mini Nasdaq futures rose +0.92% [1] Economic Indicators - Weekly initial unemployment claims fell by -33,000 to 231,000, indicating a stronger labor market than the expected 240,000 [5] - The September Philadelphia Fed business outlook survey rose by +23.5 to an 8-month high of 23.2, surpassing expectations of 1.7 [5] - August leading indicators fell -0.5% month-over-month, which was weaker than the expected -0.2% and marked the largest decline in four months [6] Sector Performance - Semiconductor stocks led the technology sector higher, with Intel surging more than +22% after Nvidia announced a $5 billion investment in the company for co-developing chips [2][12] - Other notable gainers in the semiconductor sector included KLA Corp, ASML Holding NV, and Applied Materials, all closing up more than +6% [12] Company News - CrowdStrike Home closed up more than +12% following an investor briefing discussing its AI strategy and a strong preliminary fiscal 2027 outlook [13] - 89bio closed up more than +85% after Roche announced its intention to acquire the company for $3.5 billion or $14.50 per share [13] - Allstate closed up more than +4% after reporting August catastrophe losses of $168 million, down -8.7% month-over-month [14] - Cooper Companies closed up more than +4% after its board approved a $1 billion increase in its stock buyback program [14] Earnings Reports - FactSet Research Systems closed down more than -10% after reporting Q4 adjusted EPS of $4.05, below the consensus of $4.15, and forecasting 2026 adjusted EPS weaker than expected [15] - Darden Restaurants closed down more than -7% after forecasting 2026 adjusted EPS below consensus [16]